William Blair analyst Andy Hsieh reiterates an Outperform rating on Viking Therapeutics (VKTX) after hosting investor meetings the company's CEO Brian Lian. The analyst continues to view Viking's risk/reward symmetry as skewed to the upside, especially with the recent sector volatility and the "continued significant valuation gap" with competitor Madrigal Pharmaceuticals (MDGL). Viking is on track to file an investigational new drug application later this year to the FDA's Division of Gastroenterology and Inborn Errors Products, which would enable the company to initiate the Phase II biopsy-confirmed nonalcoholic steatohepatitis study, Hsieh tells investors in a research note.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here